Latest Financing News

Elanor Commercial Property Fund's Independent Board Committee has unanimously recommended that securityholders reject the unsolicited takeover offer from Lederer Group, citing undervaluation and lack of control premium.

BPH Global Ltd reports a robust 50.9% increase in seaweed sales for July 2025, driven by strong domestic demand in Indonesia and plans to expand internationally.

Autosports Group Limited reported a robust FY25 with normalised NPBT of $47.1 million, driven by strategic acquisitions and greenfield expansions. The company is poised for further growth in FY26, targeting a doubling of its Mercedes-Benz footprint and continued market consolidation.

IDT Australia Limited reported a strong 40.6% increase in revenue to $19.86 million for FY25, driven by growth in advanced therapies and contract disbursements. However, the company’s net loss widened to $8.06 million as it transitions from its ‘Rebuild Strategy’ to a new phase focused on sustainable profitability.

Peter Warren Automotive Holdings reported a steady FY25 underlying profit before tax of $22.3 million, maintaining revenue despite a challenging new car market and declaring a final dividend. The group’s strategic focus on cost control, inventory discipline, and acquisitions underpinned its resilience.

Netwealth Group Limited has reported a stellar FY25 with record funds under administration net flows of $15.8 billion and a 31% rise in EBITDA, underpinned by strong adviser growth and strategic technology investments.

Pengana International Equities Limited (ASX, PIA) proposes a strategic portfolio enhancement by adding global private credit exposure, aiming to significantly lift fully franked dividends and diversify income streams.

Pengana International Equities is set to diversify its portfolio by adding global private credit exposure, aiming to increase earnings and fully franked dividends by 56%, with monthly payments starting November 2025.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.

QuickFee Limited reports a robust 25% revenue increase in FY25 alongside a return to profitability, setting a confident earnings guidance for FY26 backed by its expanding Connect platform.

Acumentis Group Limited reported a 4% revenue increase and a 35% jump in operating profit for FY25, driven by growth in corporate and private clients despite a government contract decline. The company declared a fully franked dividend and outlined a cautiously optimistic outlook for FY26.